JGJyothis T. George

Jyothis T. George

*This is an algorithmically generated author record based on publicly available information.

Jyothis T. George has a total of 145 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • 131-LB: Empagliflozin Reduces the Total Burden of All-Cause Hospitalizations (ACH) and Mortality in EMPA-REG Outcome

    by Silvio E. Inzucchi, Bernard Zinman, Christoph Wanner, David H. Fitchett, Stefan Anker, Stuart Pocock, Stefan Kaspers, Jyothis T. George, Odd Erik Johansen, Waheed Jamal, et al.

    Aims: In EMPA-REG OUTCOME, empagliflozin (EMPA) reduced hospitalization for heart failure risk and cardiovascular (CV) mortality in patients (pts) with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease (ASCVD). We assessed the effect of EMPA on total (first and recurrent) events of ACH and all-cause mortality (ACM). Methods: Pts were randomized to EMPA 10 mg, EMPA 25 mg, or placebo (PBO). We assessed the effect of EMPA pooled vs. PBO on total events of a composite of ACH or ACM using a negative binomial model. Results: Among 7,020 pts (mean [SD] age 63 [9] years), there were 5,399 total events of ACH and ACM. The most frequent hospitalizations were cardiac disorders (1,339), infections and infestations (841), and nervous system disorders (511); ACM: n=463. EMPA reduced the risk of total events of ACH or ACM by 19% vs. PBO (event rate ratio (95% CI): 0.81 (0.74, 0.89), p<0.0001) (Figure); ACH alone 0.83 (0.76, 0.91), ACM alone 0.69 (0.57, 0.83). Across most hospitalization categories, a numerically smaller proportion of pts experienced events with EMPA vs. PBO. The estimated number of total ACH or ACM events prevented with EMPA was 793.3; number of pts needed to treat (NNT) over 3 years to prevent one event was 5.4 (3.8, 9.3). Conclusion: EMPA reduced risk of the total burden of ACH and mortality in pts with T2D and ASCVD, with a clinically relevant number of events prevented and a low NNT. Disclosure: S.E. Inzucchi: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Lexicon Pharmaceuticals, Inc., Novo Nordisk A/S, Sanofi. Consultant; Self; Abbott, Merck & Co., Inc., vTv Therapeutics. B. Zinman: Advisory Panel; Self; Abbott, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., Novo Nordisk Inc., Sanofi-Aventis. C. Wanner: Advisory Panel; Self; Eli Lilly and Company, Merck & Co., Inc., Mundipharma International. Consultant; Self; Boehringer Ingelheim (Canada) Ltd., Sanofi Genzyme. Speaker’s Bureau; Self; AstraZeneca. Other Relationship; Self; Boehringer Ingelheim International GmbH. D.H. Fitchett: Consultant; Self; AstraZeneca, Boehringer Ingelheim International GmbH. Speaker’s Bureau; Self; Lilly Diabetes. Other Relationship; Self; Novo Nordisk Inc. S. Anker: Research Support; Self; Abbott Laboratories, Vifor Pharma Group. Other Relationship; Self; AstraZeneca, Bayer AG, Boehringer Ingelheim International GmbH, Cardiac Dimension, Impulse Dynamics, Novartis AG, Respicardia, St. Jude Medical, Vifor Pharma Group. S. Pocock: Consultant; Self; Boehringer Ingelheim International GmbH. S. Kaspers: Employee; Self; Boehringer Ingelheim International GmbH. J.T. George: Employee; Self; Boehringer Ingelheim International GmbH. O. Johansen: Employee; Self; Boehringer Ingelheim International GmbH. W. Jamal: Employee; Self; Boehringer Ingelheim International GmbH. S. Hantel: Employee; Self; Boehringer Ingelheim Pharma GmbH & Co. KG. S.S. Lund: Employee; Self; Boehringer Ingelheim International GmbH. Stock/Shareholder; Self; Novo Nordisk A/S. Other Relationship; Self; Investment funds. Funding: Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance


  • 1199-P: Analysis of Patient Preferences for Adjunct Therapy to Insulin in T1D

    by Bruce A. Perkins, Julio Rosenstock, Jay S. Skyler, Lori M. Laffel, David Cherney, Chantal Mathieu, Christianne Pang, Richard Wood, Ona Kinduryte, Jyothis George, et al.

    Recent ADA/EASD recommendations emphasize the importance of the patient role in therapy decisions. Adjunct to insulin SGLT inhibitor (SGLTi) therapy for T1D has been evaluated in RCTs but patient reaction to the benefit-risk profile of these agents is unknown. We aimed to objectively evaluate patient preferences for different therapy options, using a Discrete Choice Experiment (DCE) form of conjoint analysis, a validated methodology. The DCE used an online survey, completed by 701 respondents with T1D (231 U.S., 242 Canada, 228 Germany), to present 6 hypothetical, masked pair-wise drug profile comparison choices composed of different benefit-risk attributes and clinical effect ranges (levels). Attributes and levels were derived from different combinations of phase 3 trial data for a low dose SGLTi (comparable to empagliflozin 2.5mg); a high dose SGLTi (comparable to sotagliflozin 400mg); and an available adjunct to insulin therapy (pramlintide 60µg TID). Based upon respondents’ choices, DCE calculated, in %, the relative importance of one attribute to another and the overall predicted therapy preferences. DKA risk was the most important attribute with a relative importance of 23% (z-test, p<0.05). Second and similarly important were HbA1c reduction (14%), risk of hypoglycemia (13%), oral vs. injection treatment (13%), and risk of genital infection (12%). Next was risk of nausea (11%); weight reduction (8%) and risk of diarrhea (7%) were least important. The predicted therapy preference share was highest for low dose SGLTi, ranked first by 83% (z-test, p10 companies). O. Kinduryte: Employee; Self; Boehringer Ingelheim International GmbH. Stock/Shareholder; Self; Novo Nordisk A/S, Zealand Pharma A/S. J. George: Employee; Self; Boehringer Ingelheim International GmbH. J. Marquard: Employee; Self; Boehringer Ingelheim International GmbH. N. Soleymanlou: Employee; Self; Boehringer Ingelheim Canada Ltd. Funding: Boehringer Ingelheim; Eli Lilly and Company

  • Open Access

    The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study

    by William G Herrington, David Preiss, Richard Haynes, Maximilian von Eynatten, Natalie Staplin, Sibylle J Hauske, Jyothis T George, Jennifer B Green, Martin J Landray, Colin Baigent, et al.

    Clinical Kidney Journal, Volume 11, Issue 6, 1 December 2018, Pages 749–761, https://doi.org/10.1093/ckj/sfy090


  • PDB63 - COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN TREATMENT IN PATIENTS WITH TYPE 2 DIABETES AND CHRONIC HEART FAILURE BASED ON SUBGROUP OF EMPA-REG OUTCOME IN THE UNITED KINGDOM

    by O. Reifsnider, A. Kansal, J. Franke, J. Lee, J.T. George, M. Brueckmann, S. Kaspers, S. Brand, A. Ustyugova, S. Linden, et al.


  • Reduction in cardiovascular death with empagliflozin is consistent across categories of baseline HbA1c and change in HbA1c: Results from EMPA-REG OUTCOME

    by Se Inzucchi, D Fitchett, C Wanner, J George, Hj Woerle, B Zinman

    Aim: In the EMPA-REG OUTCOME trial, empagliflozin given in addition to standard of care significantly reduced cardiovascular (CV) death vs. placebo (HR 0.62; 95% CI 0.49, 0.77) in patients with type 2 diabetes (T2DM) and established CV disease. We investigated whether baseline HbA1c or change in HbA1c influenced the effect of empagliflozin on CV death. Methods: Patients were randomised to empagliflozin 10 mg, empagliflozin 25 mg, or placebo. Background glucose-lowering therapy was to remain unchanged for 12 weeks, then adjusted to achieve glycaemic control according to local guidelines. CV death was analysed in the pooled empagliflozin group vs. placebo by categories of baseline HbA1c and change in HbA1c from baseline to the last value in the trial, using a Cox proportional hazards model. Results: A total of 7020 patients were treated. Median observation time was 3.1 years. In patients with baseline HbA1c < 7%, 7.0 to < 8.0%, 8.0 to < 9.0% and ≥9.0%, HRs for CV death were 0.30 (95% CI 0.12, 0.80), 0.59 (0.42, 0.83), 0.67 (0.45, 0.99) and 0.76 (0.44, 1.31), respectively (p = 0.4104 for treatment by subgroup interaction). In patients with reduction in HbA1c from baseline of ≥0.3% and < 0.3%, HRs for CV death were 0.58 (95% CI 0.42, 0.79) and 0.65 (0.47, 0.90) respectively (p = 0.5996 for interaction). Conclusion: In patients with T2DM and established CV disease, the reduction in the risk of CV death with empagliflozin vs. placebo was not affected by baseline HbA1c or the change in HbA1c from baseline to the last value in the trial.


  • Neurokinin B receptor antagonist limits kisspeptin-10 induced LH secretion in women

    by Karolina Skorupskaite, Jyothis T George, Richard A Anderson

    Background: The hypothalamic neuropeptides kisspeptin and neurokinin B (NKB) are both obligate for normal gonadotrophin secretion. Studies in patients with loss-of-function mutations in NKB signalling suggest that kisspeptin is functionally upstream of NKB, but this hierarchy is unexplored in healthy men and women. We hypothesised that kisspeptin augmentation of estrogen-induced mid-cycle LH secretion will not be abrogated by pharmacological blockade of NKB. Methods: Ten healthy women were administered NKBR antagonist AZD4901 (AstraZeneca) 40 mg po bd (or no treatment controls, n=9) from cycle day 4–5 for 6 days; transdermal estradiol (200 μg/day) was applied after 5 days and induced LH secretion 48 h later (controls: 0 h: 4.4±0.6; 24 h: 3.1±0.3; 48 h: 8.6±1.0; 72 h 9.1±2.8 IU/l, Pt-test and ANOVA with Bonferroni multiple comparison post hoc analysis. Results: NKBR antagonist did not affect estrogen-induced LH secretion (48 h: 9.7±2.2; 72 h: 6.5±1.2 IU/l vs estrogen only, ns). During estrogen treatment, kisspeptin-10 stimulated LH secretion, from 3.8±0.6 to 17.3±4.3 IU/l (PPP<0.05). Conclusions: Kisspeptin-10 advanced estrogen-induced LH secretion. Treatment with the NKB antagonist did not affect the positive feedback response to estrogen, and while the immediate LH response to kisspeptin was maintained, the duration was shortened. These data suggest neurokinin B is predominantly proximal to kisspeptin in the regulation of GnRH, but indicate a complex interaction between these neuropeptides.

  • Open Access

    Differences in level of confidence in diabetes care between different groups of trainees: the TOPDOC diabetes study

    by Christopher J Smith, Jyothis T George, David Warriner, David J McGrane, Kavithia S Rozario, Hermione C Price, Emma G Wilmot, Partha Kar, Irene M Stratton, Edward B Jude, et al.


  • How does obesity affect fertility in men – and what are the treatment options?

    by Victoria J. Stokes, Richard A. Anderson, Jyothis T. George

    Summary: Adiposity is associated with reduced fertility in men. The aetiology is multifactorial, with obese men at greater risk of suffering from impaired spermatogenesis, reduced circulating testosterone levels, erectile dysfunction and poor libido. The diagnosis and treatment of reduced fertility observed in obese men therefore requires insight into the underlying pathology, which has hormonal, mechanical and psychosocial aspects. This article summarises the current epidemiological, experimental and clinical trial evidence from the perspective of a practicing clinician. The following conclusions and recommendations can be drawn: Obesity is associated with low serum testosterone concentrations, but treatment with exogenous testosterone is likely to adversely impact on fertility. It is important to discuss this with men prior to initiation of testosterone therapy. Obesity adversely affects sperm concentration and may affect sperm quality. However, whether or not weight loss will correct these factors remain to be established. Oestrogen receptor modulators (and aromatase inhibitors) are unlicensed in the treatment for male hypogonadism and/or infertility. These treatments should hence be considered experimental approach until ongoing clinical trials report their outcomes.


  • YDEF training survey 2014

    by Paul Grant, Ali Chakera, Kelly Cheer, Roselle Herring, Rahat Maitland, Jyothis George, Milan Piya, Stuart Little

  • Top Cited Papers
    Open Access

    The kisspeptin-GnRH pathway in human reproductive health and disease

    by Karolina Skorupskaite, Jyothis T George, Richard A Anderson

    The discovery of kisspeptin as key central regulator of GnRH secretion has led to a new level of understanding of the neuroendocrine regulation of human reproduction. The related discovery of the kisspeptin-neurokinin B-dynorphin (KNDy) pathway in the last decade has further strengthened our understanding of the modulation of GnRH secretion by endocrine, metabolic and environmental inputs. In this review, we summarize current understanding of the physiological roles of these novel neuropeptides, and discuss the clinical relevance of these discoveries and their potential translational applications. A systematic literature search was performed using PUBMED for all English language articles up to January 2014. In addition, the reference lists of all relevant original research articles and reviews were examined. This review focuses mainly on published human studies but also draws on relevant animal data. Kisspeptin is a principal regulator of the secretion of gonadotrophins, and through this key role it is critical for the onset of puberty, the regulation of sex steroid-mediated feedback and the control of adult fertility. Although there is some sexual dimorphism, both neuroanatomically and functionally, these functions are apparent in both men and women. Kisspeptin acts upstream of GnRH and, following paracrine stimulatory and inhibitory inputs from neurokinin B and dynorphin (KNDy neuropeptides), signals directly to GnRH neurones to control pulsatile GnRH release. When administered to humans in different isoforms, routes and doses, kisspeptin robustly stimulates LH secretion and LH pulse frequency. Manipulation of the KNDy system is currently the focus of translational research with the possibility of future clinical application to regulate LH pulsatility, increasing gonadal sex steroid secretion in reproductive disorders characterized by decreased LH pulsatility, including hypothalamic amenorrhoea and hypogonadotropic hypogonadism. Conversely there may be scope to reduce the activity of the KNDy system to reduce LH secretion where hypersecretion of LH adds to the phenotype, such as in polycystic ovary syndrome. Kisspeptin is a recently discovered neuromodulator that controls GnRH secretion mediating endocrine and metabolic inputs to the regulation of human reproduction. Manipulation of kisspeptin signalling has the potential for novel therapies in patients with pathologically low or high LH pulsatility.